Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169 | Completed Phase 1 Results

• 1 other identifier: 20-A63-AU
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The object of this study is to compare the rate and extent of absorption of an investigational formulation of buprenorphine 8 mg sublingual tablets manufactured by Barr Laboratories, Inc. to an equivalent oral dose of the commercially available reference product, Subutex® manufactured by Reckitt Benckiser, following and overnight fast of at least 10 hours.

Conditions

Healthy

Keywords

Bioequivalence; Healthy

Outcome Measures

Primary Outcomes (3)

• Cmax of Buprenorphine.

  Bioequivalence based on Buprenorphine Cmax (maximum observed concentration of drug substance in plasma).

  Blood samples collected over a 144 hour period.

• AUC0-t for Buprenorphine.

  Bioequivalence based on Buprenorphine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

  Blood samples collected over a 144 hour period.

• AUC0-inf for Buprenorphine.

  Bioequivalence based on Buprenorphine AUC0-inf (area under the concentration-time curve from time zero to infinity).

  Blood samples collected over a 144 hour period.

Secondary Outcomes (3)

• Cmax for Norbuprenorphine.

  Blood samples collected over a 144 hour period.

• AUC0-t for Norbuprenorphine.

  Blood samples collected over a 144 hour period.

• AUC0-inf for Norbuprenorphine.

  Blood samples collected over a 144 hour period.

Study Arms (2)

Investigational Test Product

EXPERIMENTAL

Buprenorphine 8 mg Sublingual Tablets

Drug: Buprenorphine

Reference Listed Drug

ACTIVE COMPARATOR

Subutex® 8 mg Sublingual Tablets

Drug: Buprenorphine

Interventions

Buprenorphine DRUG

8 mg Sublingual Tablets

Investigational Test Product

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject must be a male or non-pregnant, non-breastfeeding female.
• Subject must be between 18 and 45 years of age (inclusive).
• Subject's Body Mass Index (BMI) must be between 18 and 30 (inclusive), and subject must weigh a minimum of 50 kg (110 lbs).
• Female subjects must agree to utilize one of the following forms of contraception from screening through 4 weeks after completion of the study. Approved forms of contraception are abstinence, double barrier, IUD in place at least 30 days prior to study drug administration, vasectomized partner, surgically sterile for at least 6 months, or at least 2 years postmenopausal.
• Subject must voluntarily consent to participate in this study and provide their written informed consent prior to completion of any study-specific procedures.
• Subject is willing and able to remain in the study unit for the entire duration of the confinement period and return for all scheduled outpatient visits.

You may not qualify if:

• History or presence of any clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
• History or presence of pancreatitis, bowel obstruction, glaucoma, enlargement of the prostate, adrenal disease, hyperthyroidism, or gallbladder disease. Subjects with a history of cholecystectomy for the treatment of gallbladder disease will be excluded.
• Females taking any oral contraceptives including estrogen and progestin combined pills, progestin-only pills, patch, or vaginal ring within 28 days prior to the first dose of study medication; using injectable contraceptives within 6 months of first dose; or who have ever had progestational hormone implants.
• Females taking hormone replacement therapy within 60 days prior to the first dose of study medication.
• Has a clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening.
• History or presence of allergic or adverse response to buprenorphine, naltrexone, or any comparable or similar product.
• Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
• Has donated blood or plasma within 30 days prior to the first dose of study medication.
• Has participated in another clinical trial within 30 days prior to the first dose of study medication.
• Has used any over-the-counter (OTC) medication, including cough and cold preparations, vitamins, and herbal supplements, within 7 days prior to the first dose of study medication.
• Has used any prescription medication within 14 days prior to the first dose of study medication.
• Has consumed beverages or food containing alcohol, caffeine/xanthine, or poppy seeds from 48 hours prior to the first dose of study medication or has consumed beverages or foods containing grapefruit from 14 days prior to the first dose of study medication.
• Has been treated with any known enzyme-altering drugs, such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
• Has smoked or used tobacco products within 60 days prior to the first dose of study medication.
• Has a history of treatment for substance abuse (including alcohol) in the past 5 years.

Sponsors & Collaborators

• Teva Pharmaceuticals USA: lead

Study Sites (1)

CEDRA Clinical Research, LLC

Austin, Texas, 78759, United States

Location

MeSH Terms

Interventions

Buprenorphine

Intervention Hierarchy (Ancestors)

Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Results Point of Contact

• Title: Associate Director, Biopharmaceutics
• Organization: TEVA Pharmaceuticals, USA

clinicaltrialqueries@tevausa.com

1-866-384-5525

Study Officials

• Frederick A Bieberdorf, M.D., CPI

  CEDRA Clinical Research, LLC

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: July 2, 2010
• First Posted: July 5, 2010
• Study Start: August 1, 2007
• Primary Completion: September 1, 2007
• Study Completion: September 1, 2007
• Last Updated: January 18, 2020
• Results First Posted: September 13, 2010

Record last verified: 2020-01

Locations

US (1)